Nexilico
Nexilico is a biotech company focused on precision microbiome engineering, utilizing an innovative, modality-agnostic AI-driven discovery platform. Their proprietary 'microbiome digital twin' technology enables microbiome precision medicine and supports the development of diverse therapeutic strategies for various diseases. As a leader in next-generation in silico microbiome technologies, Nexilico aims to unlock the microbiome's potential to solve complex health challenges. The company has received significant funding from sources like the NIH and NSF, and has formed collaborations with entities such as Siolta Therapeutics and NVIDIA. Key personnel include co-founders Mohammad Soheilypour (CEO) and Mohammad Mofrad (Chief Scientific Advisor), along with Director of R&D Wyatt Hartman.
Nexilico
Nexilico is a biotech company focused on precision microbiome engineering, utilizing an innovative, modality-agnostic AI-driven discovery platform. Their proprietary 'microbiome digital twin' technology enables microbiome precision medicine and supports the development of diverse therapeutic strategies for various diseases. As a leader in next-generation in silico microbiome technologies, Nexilico aims to unlock the microbiome's potential to solve complex health challenges. The company has received significant funding from sources like the NIH and NSF, and has formed collaborations with entities such as Siolta Therapeutics and NVIDIA. Key personnel include co-founders Mohammad Soheilypour (CEO) and Mohammad Mofrad (Chief Scientific Advisor), along with Director of R&D Wyatt Hartman.